Octapharma Pharmazeutika
For more than 40 years, Octapharma has grown into the world's largest privately owned and independent plasma fractionator, with more than 11,000 dedicated employees manufacturing high-quality, life-saving medicines derived from human plasma and human cell lines. Every day, we work to support the treatment of patients in 120 countries and, in doing so, improve their lives. Our efforts focus on three therapeutic areas: immunotherapy, hematology, and critical care. Octapharma operates seven research and development sites, five production facilities in Austria, France, Germany, and Sweden, as well as over 190 plasma donation centers across Europe and the United States. Vienna is home to Octapharma’s largest production site, covering the entire value chain from R&D and production to support functions. More than 1,500 employees from 37 nations work at the Vienna site.